Titre :

NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Auteur(s) :

Turck, Turck [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Bresson, Jean-Louis [Auteur]
Burlingame, Barbara [Auteur]
Dean, Tara [Auteur]
Fairweather-Tait, Susan [Auteur]
Heinonen, Marina [Auteur]
Hirsch-Ernst, Karen-Ildico [Auteur]
Mangelsdorf, Inge [Auteur]
Mcardle, Harry J. [Auteur]
Naska, Androniki [Auteur]
Neuhauser-Berthold, Monika [Auteur]
Nowicka, Grazyna [Auteur]
Pentieva, Kristina [Auteur]
Sanz, Yolanda [Auteur]
Sjodin, Anders [Auteur]
Stern, Martin [Auteur]
Tome, Daniel [Auteur]
Van Loveren, Henk [Auteur]
Vinceti, Marco [Auteur]
Willatts, Peter [Auteur]
Martin, Ambroise [Auteur]
Strain, Sean [Auteur]
Siani, Alfonso [Auteur]

Titre de la revue :

EFSA Journal

Nom court de la revue :

EFSA J.

Numéro :

16

Date de publication :

2018-01-01

ISSN :

1831-4732

Mot(s)-clé(s) en anglais :

NWT-02
health claim
vision acuity
vision

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Following an application from Newtricious R&D B.V., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on ...
Lire la suite >Following an application from Newtricious R&D B.V., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to NWT-02 and a reduction of the loss of vision. The food proposed by the applicant as the subject of the health claim is NWT-02. NWT-02 is standardised by its content in lutein (≥ 1.10 mg), zeaxanthin (≥ 0.20 mg) and docosahexaenoic acid (DHA) (≥ 170 mg). The Panel considers that the food/constituent that is the subject of the health claim, NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, is sufficiently characterised. The claimed effect proposed by the applicant is ‘reduces loss of vision’. The target population proposed by the applicant is ‘healthy adults over 50 years of age’. The Panel considers that a reduction of the loss of vision is a beneficial physiological effect. The applicant provided two human intervention studies for the scientific substantiation of the claim. The Panel considers that the only study from which conclusions can be drawn for the scientific substantiation of the claim did not show an effect of NWT-02 on vision. The Panel concludes that a cause and effect relationship has not been established between the consumption of NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, and a reduction of the loss of vision.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2019-10-22T08:09:34Z
2023-12-01T15:51:33Z
2023-12-01T15:53:06Z